EXTRA - evaluation of xeloda treatment with radiotherapy in anal cancer. A mulitcentre phase II study of chemoradiation and oral xeloda [capecitabine] and mitomycin C for patients with anal cancer

Trial Profile

EXTRA - evaluation of xeloda treatment with radiotherapy in anal cancer. A mulitcentre phase II study of chemoradiation and oral xeloda [capecitabine] and mitomycin C for patients with anal cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Mitomycin
  • Indications Anal cancer
  • Focus Therapeutic Use
  • Acronyms EXTRA
  • Most Recent Events

    • 16 Mar 2010 Planned number of patients changed from 10 to 30 and lead trial investigator (Glynne-Jones R) added as reported by United Kingdom Clinical Research Network.
    • 25 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top